Pfizer Inc.
Pfizer has stayed in a narrow range of $32 to $42 in the past year. However, we feel two recent developments will let it move higher in the next few years and spur your returns.
The first is Pfizer’s development of an effective COVID-19 vaccine....
A: Three main factors continue to drive demand for healthcare products and services: the rapid aging of the population in developed countries; the expansion of medical services in developing countries; and significant new developments in the field of medical technology and innovation.
The iShares Global Healthcare ETF, $80.06, symbol IXJ on New York (Units outstanding: 35.3 million; Market cap: $2.8 billion; www.ishares.com/us), invests globally in healthcare companies.
The fund tracks the S&P Global Healthcare Index....
The iShares Global Healthcare ETF, $80.06, symbol IXJ on New York (Units outstanding: 35.3 million; Market cap: $2.8 billion; www.ishares.com/us), invests globally in healthcare companies.
The fund tracks the S&P Global Healthcare Index....
While some businesses—and especially “work-from-home” stocks like Zoom—have thrived during the pandemic, others continue to suffer. This includes airlines, hotels, movie theatres, automakers, oil and gas producers and many brick-and-mortar retailers.
Here’s a look at several ETFs that generally hold stocks that have underperformed in the past year, mostly due to COVID-19....
Here’s a look at several ETFs that generally hold stocks that have underperformed in the past year, mostly due to COVID-19....
Study after study has shown that after an initial adjustment period of a few months, spinoffs tend to outperform groups of comparable stocks for several years. Still, in looking at two recent spinoff deals, we feel the spinoff of Pfizer’s generic drug business is more attractive than Artis REIT’s plan to separate its Canadian retail properties.
PFIZER INC....
Thermo Fisher keeps soaring for our readers—it’s up 39.4% since we first recommended it in our May 2020 issue at $325.83. Thermo Fisher doesn’t make vaccines. But it does provide key equipment that will be needed regardless of whose vaccines succeed. Thermo Fisher is a Power Buy for our Power Growth Investors.
THERMO FISHER SCIENTIFIC INC....
THERMO FISHER SCIENTIFIC INC....
PFIZER INC. $36 is a buy. The prescription drugmaker (New York symbol PFE; Income Portfolio, Manufacturing & Industry sector; Shares outstanding: 5.6 billion; Market cap: $201.6 billion; Dividend yield: 4.2%; Dividend Sustainability Rating: Highest; www.pfizer.com) last raised its quarterly dividend in March 2020....
We now see several promising opportunities emerging in the pharmaceutical drug industry, and we will probably recommend more drug stocks in the next few years. For now, we feel Pfizer offers our readers the best combination of growth and income in a pharma stock....
We go back a long way with medical-device supplier Baxter International. The stock is up a whopping 674.9% since we recommended it at $16.75 a share (adjusted for two 2-for-1 share splits) in our December 1999 inaugural issue of Wall Street Stock Forecaster....
Here’s the text of the most-recent letter I sent to our Portfolio Management clients last month:
“We’ve generally stayed out of drug stocks for much of the past two decades, but that will change over the next year or two. In fact, we now expect to see many great investment opportunities in drug stocks throughout the 2020s....
“We’ve generally stayed out of drug stocks for much of the past two decades, but that will change over the next year or two. In fact, we now expect to see many great investment opportunities in drug stocks throughout the 2020s....
PFIZER INC. $37 is a buy. The company (New York symbol PFE; Income Portfolio, Manufacturing & Industry sector; Shares outstanding: 5.6 billion; Market cap: $207.2 billion; Price-to-sales ratio: 4.1; Dividend yield: 4.1%; TSINetwork Rating: Above Average; www.pfizer.com) saw its revenue in the first quarter of 2020 fall 8.3%, to $12.03 billion from $13.12 billion a year earlier....